Carsten Browall proposed as new Chairman of Vitrolife AB (publ)
The Election Committee of Vitrolife AB (publ) has proposed Carsten Browall as the new Chairman of the Board. Carsten Browall is today a member of the company’s Board and he has many years of experience in medical device and the healthcare sector.
Vitrolife’s Election Committee today announced that it proposes that the Annual General Meeting elect Carsten Browall as the company’s new Chairman of the Board. Carsten Browall has been a member of the Vitrolife Board since 2012 and has many years of experience from executive positions within medical device and the healthcare sector, amongst other things from Unfors RaySafe, Mölnlycke Health Care, Nobel Biocare and Capio.
“It is an honour to be asked to take over the position of Chairman and it will be immensely exciting to continue the work on Vitrolife’s successful journey together with the Board and the executive management,” says Carsten Browall.
The present Chairman of the Board, Patrik Tigerschiöld, has declined reelection after 13 years on the Board and 11 years as its Chairman.
“It has been a very successful period for Vitrolife and it now feels natural to hand over the Chairman’s gavel to Carsten Browall, who I am convinced is the right person to lead the Board in the company’s next phase. I would like to make clear that my decision to leave the Board shall in no way be seen as Bure Equity, which is the largest owner, having a changed view of its shareholding in Vitrolife,” says Patrik Tigerschiöld.
Gothenburg, March 25, 2013
VITROLIFE AB (publ)
Queries should be addressed to:
Patrik Tigerschiöld, Chairman of the Board, phone 46 8 614 00 20
Carsten Browall, Board member, phone + 46 70 255 65 32
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on March 25, at 5.00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is a global medical device Group. Vitrolife Fertility product area develops, produces and markets products for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife has approximately 230 employees and the company's products are sold in about 100 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: firstname.lastname@example.org. Website: www.vitrolife.com/